Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 16 of the 17 references it cites were found in a registry or an index.

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

de Bono, Johann Sebastian, Oudard, Stephane, Ozguroglu, Mustafa, Hansen, Steinbjørn, Machiels, Jean-Pascal, Kocak, Ivo, Gravis, Gwenaëlle, Bodrogi, Istvan, Mackenzie, Mary J, Shen, Liji, Roessner, Martin, Gupta, Sunil, Sartor, A Oliver · 2010 · The Lancet

Abstract

Background Cabazitaxel is a novel tubulin-binding taxane drug with antitumour activity in docetaxel-resistant cancers. We aimed to compare the efficacy and safety of cabazitaxel plus prednisone with those of mitoxantrone plus prednisone in men with metastatic castration-resistant prostate cancer with progressive disease after docetaxel-based treatment. Methods We undertook an open-label randomised phase 3 trial in men with metastatic castration-resistant prostate cancer who had received previous hormone therapy, but whose disease had progressed during or after treatment with a docetaxel-containing regimen. Participants were treated with 10 mg oral prednisone daily, and were randomly assigned to receive either 12 mg/m(2) mitoxantrone intravenously over 15-30 min or 25 mg/m(2) cabazitaxel intravenously over 1 h every 3 weeks. The random allocation schedule was computer-generated; patients and treating physicians were not masked to treatment allocation, but the study team was masked to the data analysis. The primary endpoint was overall survival. Secondary endpoints included progression-free survival and safety. Analysis was by intention to treat. This study is registered at ClinicalTrials.gov, NCT00417079. Findings 755 men were allocated to treatment groups (377 mitoxantrone, 378 cabazitaxel) and were included in the intention-to-treat analysis. At the cutoff for the final analysis (Sept 25, 2009), median survival was 15·1 months (95% CI 14·1-16·3) in the cabazitaxel group and…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(10)61389-x

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 17 references

Research works printed but not linked: 1

  1. Aller, 2000, In vitro activity of TXD258 in chemotherapeutic resistant tumor cell lines, Proc Am Assoc Cancer Res, 41, 303

Cited by

See all 3,318

Metadata

Authors
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., Roessner, M., Gupta, S., & Sartor, A. O.
Affiliations
  • Odense University Hospital (DK)
  • Cliniques Universitaires Saint-Luc (BE)
  • London Health Sciences Centre (CA)
Venue
The Lancet
Publisher
Elsevier BV
Published
2010-10
Volume
376
Issue
9747
Pages
1147-1154
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2123526148
Cited by
3,318
References
17
Citations by year
2026: 82 · 2025: 108 · 2024: 125 · 2023: 176 · 2022: 182 · 2021: 207 · 2020: 209 · 2019: 226 · 2018: 241 · 2017: 245 · 2016: 261 · 2015: 269 · 2014: 285 · 2013: 278 · 2012: 240
FWCI
185.29
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion)
  • DIAL (Catholic University of Leuven) (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
  • Health Sciences › Medicine › Oncology › Bone health and treatments
Keywords
metastatic castration-resistant prostate cancer, cabazitaxel, mitoxantrone, prednisone, docetaxel resistance, second-line chemotherapy, overall survival, progression-free survival, taxanes, anthracyclines, corticosteroids, safety and tolerability, intention-to-treat analysis, hazard ratio
MeSH terms
Docetaxel, Administration, Oral, Aged, Androgen Antagonists, Antineoplastic Combined Chemotherapy Protocols, Drug Administration Schedule, Humans, Infusions, Intravenous, Male, Middle Aged, Mitoxantrone, Neutropenia, Pain Measurement, Prednisone, Prostatic Neoplasms, Biomarkers, Tumor, Treatment Outcome, Treatment Failure, Prostate-Specific Antigen, Disease Progression, Disease-Free Survival, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm, Taxoids, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. https://app.cochat.ai/papers/10.1016/s0140-6736(10)61389-x
The paper
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., Roessner, M., Gupta, S., & Sartor, A. O. (2010). Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. The Lancet. https://doi.org/10.1016/s0140-6736(10)61389-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.